Trial Profile
Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Anti-CD34 monoclonal antibody/sirolimus (Primary) ; Clopidogrel
- Indications Coronary artery disease; Myocardial infarction; Unstable angina pectoris
- Focus Adverse reactions
- Acronyms COSTA
- 17 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 06 Apr 2016 New trial record